AI-generated summary
In this double-blind, placebo-controlled trial, 47 patients with primary or secondary Raynaud's phenomenon received either low level laser irradiation or placebo irradiation. The authors report that both groups had fewer and milder attacks, with greater improvement in the laser group at 6 weeks and 3 months, and better thermographic response to cold challenge only in the laser group.
- Participants
- 47
- Who or what was studied
- Patients with primary or secondary Raynaud's phenomenon
- Limits stated in the abstract
- The abstract reports a relatively small sample split into two groups, and the placebo group also improved, so the size of the laser-specific benefit is uncertain.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on econtent.hogrefe.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Laser, Visual analogue scale, Placebo-controlled, Pilot study. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.